(CANCER HEMATOPOIESIS AND IMMUNOLOGY) The mission of Cancer Hematopoiesis and Immunology (CHI) Program is hewed to the tenet of collaborative transdisciplinary research that is aligned with the UMCCC strategic research priorities. Members of the CHI Program are committed to the pursuit of research that defines the fundamental roles of immune and non- immune hematopoietic cells in cancer as well as post-transplantation therapies. Working under the broad theme of cellular and innate immunity, normal and malignant hematopoiesis, and hematopoietic stem cell transplantation biology, the CHI Program seeks to develop translational approaches that will improve hematopoietic cell transplantation (HCT) outcomes and hasten the development of novel vaccination strategies. Toward these goals, the CHI Program is a diverse, interdisciplinary research group comprised of 24 members from 10 departments within three University of Michigan schools/colleges. The CHI Program has $10.3M in annual direct funding (88% peer-reviewed), with $2.7M from the NCI, $5.3M from other NIH sources and $2.3M in additional support. During the past project period, the Program generated 376 publications, including high impact reports appearing in Cell, Nature, Science, NEJM, and the JCI. The CHI Program enjoys strong interactions with other UMCCC members, underlined by 24% of their publications arising from intra- programmatic efforts and 43% from inter-programmatic collaborations. To build on these advances, Program aims include: 1) elucidate molecular mechanisms regulating normal immune/non-immune hematopoietic cell function during homeostasis and their alterations in cancer and HCT, 2) characterize the role of the tissue microenvironment in controlling the function and regulation of immune cells in cancer, hematopoiesis and HCT and 3) define key concepts, approaches, and reagents in preclinical studies to translate the most compelling advances into the clinic via collaboration with the Translational and Clinical Research (TACR) Program. As such, CHI Program members support the UMCCC mission by performing state-of-the-art research underlying both major and less common cancer types within our catchment area, while training the next generation of cancer researchers, and promoting collaboration with other UMCCC Programs and beyond.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046592-29
Application #
9488242
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-06-01
Budget End
2019-05-31
Support Year
29
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Feinberg, Tamar Y; Zheng, Huarui; Liu, Rui et al. (2018) Divergent Matrix-Remodeling Strategies Distinguish Developmental from Neoplastic Mammary Epithelial Cell Invasion Programs. Dev Cell 47:145-160.e6
Boonstra, Philip S; Barbaro, Ryan P (2018) Incorporating historical models with adaptive Bayesian updates. Biostatistics :
Johnson, Allison M; Roach, James P; Hu, Anna et al. (2018) Connexin 43 gap junctions contribute to brain endothelial barrier hyperpermeability in familial cerebral cavernous malformations type III by modulating tight junction structure. FASEB J 32:2615-2629
Sucularli, Ceren; Thomas, Peedikayil; Kocak, Hande et al. (2018) High-throughput gene expression analysis identifies p53-dependent and -independent pathways contributing to the adrenocortical dysplasia (acd) phenotype. Gene 679:219-231
Hrycaj, Steven M; Marty-Santos, Leilani; Cebrian, Cristina et al. (2018) Hox5 genes direct elastin network formation during alveologenesis by regulating myofibroblast adhesion. Proc Natl Acad Sci U S A 115:E10605-E10614
Subramanian, Chitra; Grogan, Patrick T; Opipari, Valerie P et al. (2018) Novel natural withanolides induce apoptosis and inhibit migration of neuroblastoma cells through down regulation of N-myc and suppression of Akt/mTOR/NF-?B activation. Oncotarget 9:14509-14523
Wang, Qing; Yan, Ran; Pinnell, Nancy et al. (2018) Stage-specific roles for Zmiz1 in Notch-dependent steps of early T-cell development. Blood 132:1279-1292
Owen, Daniel Rocky; Boonstra, Phillip S; Viglianti, Benjamin L et al. (2018) Modeling Patient-Specific Dose-Function Response for Enhanced Characterization of Personalized Functional Damage. Int J Radiat Oncol Biol Phys 102:1265-1275
Dame, Michael K; Attili, Durga; McClintock, Shannon D et al. (2018) Identification, isolation and characterization of human LGR5-positive colon adenoma cells. Development 145:
Abel, Ethan V; Goto, Masashi; Magnuson, Brian et al. (2018) HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties. Elife 7:

Showing the most recent 10 out of 1493 publications